Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zorecimeran
- Development stage
- Discontinued
- Lead developer
- CureVac
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Zorecimeran (CVnCoV) is a first-generation, non-replicating messenger RNA (mRNA) vaccine developed by CureVac for the prevention of COVID-19. It utilizes lipid nanoparticle (LNP) technology to deliver mRNA encoding the full-length SARS-CoV-2 spike protein. Unlike some other mRNA vaccines, zorecimeran used unmodified RNA. Despite reaching Phase 3 clinical trials, the candidate demonstrated a disappointing 48% overall efficacy against COVID-19 of any severity, which the company attributed to the prevalence of multiple virus variants during the trial period. Consequently, CureVac withdrew the vaccine from the European Medicines Agency (EMA) regulatory approval process in October 2021 to focus on second-generation mRNA vaccine candidates developed in collaboration with GSK.
- Brand names
- CVnCoV
- Other names
- CVnCoV
02
Targets
SARS-CoV-2 spikeACE2 (Angiotensin-converting enzyme 2)
Beyond the preview
Go deeper on zorecimeran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zorecimeran.